ReviewCancers2023
Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Machine Learning for Multi-Omics Characterization of Blood Cancers: A Systematic Review.Cells · 2025Pooled it
- Evaluation of the Usefulness of Machine Learning and Artificial Intelligence on Hyperspectral Images in the Diagnosis of Myelodysplastic Syndrome.Journal of biophotonics · 2026Article
- Mapping the research landscape of myelodysplastic syndromes: a scientometric analysis (2014-2025).Clinical and experimental medicine · 2026Article
- Novel Approaches to the Management of Myelodysplastic Syndromes: The Roles of Artificial Intelligence and Oxidative Stress Biomarkers.Hematology reports · 2026Review
- Artificial intelligence reshaping the paradigm of hematologic malignancy diagnosis and treatment: From static assessment to dynamic precision management.Annals of hematology · 2026Review
- Artificial intelligence in haematology laboratory diagnosis: Current applications, challenges, and future directions.African journal of laboratory medicine · 2026Review
- Survival Prediction in Allogeneic Haematopoietic Stem Cell Transplant Recipients Using Pre- and Post-Transplant Factors and Computational Intelligence.Journal of cellular and molecular medicine · 2025Article
- Integrating Molecular Alterations with Immunophenotype and Clinical Characteristics in Myelodysplastic Syndromes: A Single-Center Study.International journal of molecular sciences · 2025Article
- Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment.Biomedicines · 2025Review
- Applications of Artificial Intelligence in Acute Promyelocytic Leukemia: An Avenue of Opportunities? A Systematic Review.Journal of clinical medicine · 2025Review
- Application of Pathomic Features for Differentiating Dysplastic Cells in Patients with Myelodysplastic Syndrome.Bioengineering (Basel, Switzerland) · 2024Article
- Advances in Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis.Current issues in molecular biology · 2024Review
- Optimization of diagnosis and treatment of hematological diseases via artificial intelligence.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic syndrome (MDS) is composed of diverse hematological malignancies caused by dysfunctional stem cells, leading to abnormal hematopoiesis and cytopenia. Approximately 30% of MDS cases progress to acute myeloid leukemia (AML), a more aggressive disease. Early detection is crucial to intervene before MDS progresses to AML. The current diagnostic process for MDS involves analyzing peripheral blood smear (PBS), bone marrow sample (BMS), and flow cytometry (FC) data, along with clinical patient information, which is labor-intensive and time-consuming. Recent advancements in machine learning offer an opportunity for faster, automated, and accurate diagnosis of MDS. In this review, we aim to provide an overview of the current applications of AI in the diagnosis of MDS and highlight their advantages, disadvantages, and performance metrics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.